Correction: Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.

Yamauchi, Hideko; Toi, Masakazu; Takayama, Shin; Nakamura, Seigo; Takano, Toshimi; Cui, Karen; Campbell, Christine; De Vos, Liesbet; Geyer, Charles; Tutt, Andrew

Yamauchi, Hideko; Toi, Masakazu; Takayama, Shin; Nakamura, Seigo; Takano, Toshimi; Cui, Karen; Campbell, Christine; De Vos, Liesbet; Geyer, Charles; Tutt, Andrew.

Afiliação

Yamauchi H; Japan Breast Cancer Research Group (JBCRG), Tokyo, Japan. hidekoyamauchi@gmail.com.
Toi M; St. Luke's International Hospital, Tokyo, Japan. hidekoyamauchi@gmail.com.
Takayama S; Japan Breast Cancer Research Group (JBCRG), Tokyo, Japan.
Nakamura S; Kyoto University Hospital, Kyoto, Japan.
Takano T; Japan Breast Cancer Research Group (JBCRG), Tokyo, Japan.
Cui K; National Cancer Center Hospital, Tokyo, Japan.
Campbell C; Japan Breast Cancer Research Group (JBCRG), Tokyo, Japan.
De Vos L; Showa University Hospital, Tokyo, Japan.
Geyer C; Japan Breast Cancer Research Group (JBCRG), Tokyo, Japan.
Tutt A; The Cancer Institute Hospital of Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan.

Breast Cancer ; 30(4): 606, 2023 Jul.

Article em En | MEDLINE | ID: mdl-37171785

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Risk_factors_studies Idioma: En Revista: Breast Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Japão

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google